A new trading day began on Tuesday, with Bioline Rx Ltd ADR (NASDAQ: BLRX) stock price down -4.42% from the previous day of trading, before settling in for the closing price of $0.47. BLRX’s price has ranged from $0.43 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 85.48%. With a float of $79.55 million, this company’s outstanding shares have now reached $79.99 million.
The firm has a total of 38 workers. Let’s measure their productivity. In terms of profitability, gross margin is 61.81%, operating margin of -204.22%, and the pretax margin is -176.67%.
Bioline Rx Ltd ADR (BLRX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Bioline Rx Ltd ADR is 0.56%, while institutional ownership is 5.32%.
Bioline Rx Ltd ADR (BLRX) Earnings and Forecasts
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.3 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 85.48% per share during the next fiscal year.
Bioline Rx Ltd ADR (NASDAQ: BLRX) Trading Performance Indicators
Here are Bioline Rx Ltd ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.19 in one year’s time.
Technical Analysis of Bioline Rx Ltd ADR (BLRX)
Analysing the last 5-days average volume posted by the [Bioline Rx Ltd ADR, BLRX], we can find that recorded value of 0.42 million was better than the volume posted last year of 0.35 million. As of the previous 9 days, the stock’s Stochastic %D was 57.13%. Additionally, its Average True Range was 0.05.
During the past 100 days, Bioline Rx Ltd ADR’s (BLRX) raw stochastic average was set at 10.24%, which indicates a significant decrease from 32.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.94% in the past 14 days, which was lower than the 78.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6037, while its 200-day Moving Average is $0.8216. Now, the first resistance to watch is $0.4808. This is followed by the second major resistance level at $0.5114. The third major resistance level sits at $0.5518. If the price goes on to break the first support level at $0.4098, it is likely to go to the next support level at $0.3694. Should the price break the second support level, the third support level stands at $0.3388.
Bioline Rx Ltd ADR (NASDAQ: BLRX) Key Stats
With a market capitalization of 36.01 million, the company has a total of 79,939K Shares Outstanding. Currently, annual sales are 4,800 K while annual income is -60,610 K. The company’s previous quarter sales were 5,390 K while its latest quarter income was 480 K.
